Ekzokrin Pankreas Hastalıkları
Özet
Ekzokrin pankreas yetmezliği (EPY), pankreastan duodenuma yetersiz enzim iletilmesiyle oluşan ve besinlerin, özellikle de yağların emilim bozukluğuna yol açan bir hastalıktır. Akut ve kronik pankreatit, cerrahi rezeksiyonlar, kistik fibrozis ve diyabet gibi durumlar bu hastalığın etiyolojisinde yer alır. Tanısı, spesifik semptomların olmaması ve testlerin uygulama zorlukları nedeniyle güçtür; ancak dışkıda elastaz-1 düzeyi ölçümü tanı için klinik pratikte sıkça tercih edilen, spesifik bir yöntemdir. EPY klinikte steatore, kilo kaybı, karın ağrısı, şişkinlik ve yağda eriyen vitaminlerin eksikliğine bağlı metabolik kemik hastalıkları ile kendini gösterir. Temel tedavisi pankreatik enzim replasman tedavisidir (PERT). PERT, yağ ve nitrojen emilimini artırarak hastaların yaşam kalitesini belirgin şekilde iyileştirir; ancak hastaların domuz kaynaklı ilaçlara karşı isteksizliği ve yanlış doz kullanımı tedavi başarısını düşürebilir.
Exocrine pancreatic insufficiency (EPI) is a clinical condition characterized by the inadequate delivery of pancreatic enzymes to the duodenum, leading to malabsorption of nutrients, particularly fats. The etiology includes acute and chronic pancreatitis, pancreatic resections, cystic fibrosis, and diabetes. Diagnosis remains challenging due to non-specific symptoms and the complexity of direct diagnostic tests; however, fecal elastase-1 measurement serves as a highly specific and practical tool in current clinical management. Clinically, EPI presents with steatorrhea, weight loss, abdominal pain, bloating, and metabolic bone diseases secondary to fat-soluble vitamin deficiencies. The cornerstone of management is pancreatic enzyme replacement therapy (PERT). PERT significantly improves fat and nitrogen absorption, thereby enhancing the patient's overall quality of life. Nonetheless, treatment compliance issues, such as reluctance toward porcine-derived enzymes and improper dosing intervals, often diminish therapeutic success.
Referanslar
Brunicardi F. C. (2016). Pancreas. Fisher W. E. (Ed.) Scwartz Cerrahinin İlkeleri içinde (1341-1393). Ankara: Güneş Tıp Kitabevi
Whitcomb DC, Lehman GA, Vasileva G, et al.: Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol. 2010; 105(10): 2276–86.
Sand J, Nordback I: Acute pancreatitis: risk of recurrence and late consequences of the disease. Nat Rev Gastroenterol Hepatol. 2009; 6(8): 470–7.
Hollemans RA, Hallensleben NDL, Mager DJ, et al.: Pancreatic exocrine insufficiency following acute pancreatitis: Systematic review and study level meta-analysis. Pancreatology. 2018; 18(3): 253–62.
Löhr JM, Dominguez-Munoz E, Rosendahl J, et al.: United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017; 5(2): 153–99
Singh VK, Haupt ME, Geller DE, et al.: Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol. 2017; 23(39): 7059–76.
Olivier AK, Gibson-Corley KN, Meyerholz DK: Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol. 2015; 308(6): G459–71.
Mohapatra S, Majumder S, Smyrk TC, et al.: Diabetes Mellitus Is Associated With an Exocrine Pancreatopathy: Conclusions From a Review of Literature. Pancreas. 2016; 45(8): 1104–10.
Struyvenberg MR, Martin CR, Freedman SD: Practical guide to exocrine pancreatic insufficiency - Breaking the myths. BMC Med. 2017; 15(1): 29.
Kuijpers TW, Alders M, Tool AT, et al. Hematologic abnormalities in Shwachman Diamond syndrome: lack of genotype-phenotype relationship. Blood 2005; 106:356.
Toskes PP, Dawson W, Curington C, et al. Kronik pankreatitte diyabetik olmayan retina anormallikleri. N Engl J Med 1979; 300:942.
Morán CE, Sosa EG, Martinez SM, et al. Pankreas yetmezliği ve steatore hastalarında kemik mineral yoğunluğu. Ben J Gastroenterol 1997; 92:867.
DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288:813.
Borowitz D, Konstan MW, O'Rourke A, et al.: Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther. 2007; 12(1): 47–52.
Löser C, Möllgaard A, Fölsch UR: Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996; 39(4): 580–6.
Sikkens EC, Cahen DL, Koch AD, et al.: The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology. 2013; 13(3): 238–42.
Perbtani Y, Forsmark CE. Update on the diagnosis and management of exocrine pancreatic insufficiency. F1000Res. 2019;8:F1000 Faculty Rev-1991. Published 2019 Nov 26. doi:10.12688/f1000research.20779.1
Ramesh H, Reddy N, Bhatia S, et al.: A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Pancreatology. 2013; 13(2): 133–9.
Trang T, Chan J, Graham DY: Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol. 2014; 20(33): 11467–85.
